Photocoagulation

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Darius M. Moshfeghi, MD, discusses results from the phase 3 BUTTERFLEYE trial.

The portability of retina diagnostic and treatment tools, such as the recently approved Lion green laser system, allows surgeons to provide care for patients in nontraditional settings.

Intravitreal anti-VEGF injections may be a good option to treat exudative retinal arterial macroaneurysms, according to a study presented at the virtual American Academy of Ophthalmology annual meeting.

The FDA has granted 510(k) clearance to Norlase’s Lion, a green laser photocoagulator integrated into an indirect ophthalmoscope, according to a press release.

Norlase has been granted CE mark for the Leaf laser for treatment of glaucoma and retinal diseases, according to a press release.

Intravitreal ranibizumab with delayed laser photocoagulation effectively treated severe zone I and posterior zone II retinopathy of prematurity, according to findings presented at the Association for Research in Vision and Ophthalmology meeting.

Higher baseline IOP and a history of cataract extraction were found to be predictors of success in a cohort of patients with glaucoma undergoing micropulse transscleral diode laser photocoagulation.

Eyes with moderately severe to severe baseline diabetic retinopathy without prior panretinal photocoagulation experienced more rapid improvements from ranibizumab treatment compared with eyes with more mild or severe diabetic retinopathy, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.

SAN FRANCISCO — At the American Academy of Ophthalmology meeting, Oliver Hvidt, CEO and co-founder of Norlase, discusses the company’s newest device, the Leaf laser photocoagulator.